Corline Biomedical reported a sharp revenue decline and significant one-time write-downs in 2024, but positioned itself for US growth with the FDA submission of the CHSTM-coated Globe® catheter and a strategic focus on medical devices.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.